This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

14 Nov 2011

Daiichi & ArQule Ink License Pact for Cancer Compound

ArQule and Daiichi Sankyoa have announced their license agreement for the development of new AKT inhibitor ARQ 092.

US biotechnology company ArQule, Inc. and Japanese firm Daiichi Sankyo, Co. Ltd. have signed a license deal under which Daiichi obtains exclusive rights for the development, manufacture and marketing of ARQ 092 on a worldwide basis.


ARQ 092 is the first compound to result from the companies’ November 2008 research collaboration using AKIP (ArQule Kinase Inhibitor Platform) technology to generate selective and potent small molecule kinase inhibitors.


ARQ 092 will be studied in cancer patients to identify its efficacy in targeting the AKT signaling pathway, which plays a role in regulating cell growth, survival, migration and angiogenesis. Patient enrollment in the Phase I trial is scheduled to open soon.


Related News